provement has been proposed in a number of reports. A rise in allergen-blocking immunoglobulin G (IgG) antibodies, particularly of IgG4 class (4 -6) , the generation of CD8 ϩ T cells modulating the IgE response (7), a reduction in numbers of mast cells and eosinophils, and inhibition of mediator release (8 -10) were found to be associated with successful SIT. Moreover, successful SIT of allergic diseases was found to correlate directly with decreased interleukin 4 (IL-4) and IL-5 production by CD4 ϩ T cells (11, 12) . A shift from T helper cell type 2 (Th2) cytokine production toward a pattern with increased interferon gamma (IFN-␥) in SIT of allergy to bee venom (BV), wasp venom, grass pollen, and house dust mites was also observed (11) (12) (13) ). It appears, however, that the induction of a state of specific unresponsiveness or anergy in peripheral T cells represents a key step in the mechanism of SIT (11, 14 -17) . The specific anergy is characterized mainly by suppressed proliferative and cytokine responses against the major allergen(s) and its T cell recognition sites (18) . Anergized T cells can be reactivated to produce either a distinct Th1 or Th2 cytokine pattern, depending on the cytokines in the tissue microenvironment, thus directing SIT toward successful or unsuccessful clinical outcome (14, 19) .
BV phospholipase A 2 (PLA) represents the major antigen and allergen of BV (20, 21) . The response to PLA provides a model especially suited with which to study the cellular and molecular mechanisms of specific immune response regulation in humans (14 -16, 20 -23) . SIT with whole BV (BV-SIT) and with short peptides bearing immunodominant T cell epitopes of PLA (PIT) was applied successfully and enabled us to study the immunological mechanisms of SIT (14 -16) .
RECENT RESULTS

Successful SIT with whole allergen or T cell epitope-containing peptides induces specific anergy in peripheral T cells
The immunological mechanism of SIT was investigated in BV-SIT and further elucidated in PIT using a mixture of three peptides representing the immunodominant T cell epitopes PLA45-62, PLA82-92, and PLA113-124 (24) . In both BV-SIT and PIT, patients who were successfully treated showed specific T cell unresponsiveness against the entire PLA allergen as well as to the three T cell epitopecontaining peptides (14 -16) . The specific proliferative T cell responses as well as the secretion of both the Th1 cytokines IL-2 and IFN-␥ and the Th2 cytokines IL-4, IL-5, and IL-13 were suppressed. The PPD or TT control responses were not affected by either treatment, indicating that the suppressive effect of SIT and PIT was specifically directed against the respective allergen (14 -16). Decreased T cell proliferative responses in SIT have been demonstrated so far in allergy to ragweed, cat dander, grass pollen, and BV (11, 12, 25, 26) . In mice, antigenic peptides of house dust mite and cat allergen were shown to induce anergy in T cells (27, 28) . Recent studies with T cell peptides of Fel d 1 indicated suppression of specific T cell reactivity by PIT in cat allergy (17, 29) .
Recently we have shown that the induction of an anergic state in Th2 cells represents an active process that is associated with increased levels of basal tyrosine kinase activity, cytokine production, and CD25 up-regulation (30) . It appears to be related to alterations in the signaling pathways mediated through the T cell receptor (TcR). Anergized Th2 cells failed to respond to anti-CD3 stimulation with either increased tyrosine kinase activity or increased levels of tyrosine phosphorylation of p56 lck and ZAP70. In addition, intracellular calcium flux, observed in untreated Th2 cells in response to anti-CD3 monoclonal antibody, was absent in anergic Th2 cells (30) .
T cell anergy in SIT results from initial IL-10 production by specific T cells.
In BV-SIT and PIT, the proliferative responses and Th1 and Th2 cytokine production against the entire antigen and the antigenic peptides decreased within 4 wk (14 -16) . At the same time, antigen-and peptide-induced secretion of IL-10 increased simultaneously after 7 days and reached maximal levels after 28 days of treatment, when the specific anergy was fully established (15) (Fig.  1A) . The suppressed PLA-specific T cell proliferative and cytokine responses could be reconstituted by ex vivo neutralization of endogenous IL-10, indicating that this cytokine is actively involved in development of anergy in specific T cells (15) (Fig.  1B) . The cellular origin of IL-10 was demonstrated by intracytoplasmic IL-10 staining in peripheral blood mononuclear cells (PBMC) and coexpression of cellular surface markers (15) . As shown in Fig. 2 , intracellular IL-10 had already increased significantly after 7 days of SIT in the antigenspecific T cell population and in activated CD4 ϩ T lymphocytes. After 4 wk of SIT, increased intracytoplasmic IL-10 was also observed in monocytes and B cells (15) . Along with the facts that anti-IL-10 inhibited the induction of anergy in T cells (15) and recovered T cells from the anergic state ( Fig. 1) , this suggests that an autocrine action of IL-10 on the T cells induces the state of peripheral anergy. This state is further maintained by IL-10 produced by monocytes, B cells, and nonspecific bystander T cells.
The same features of specific anergy were found in healthy beekeepers who were multiply stung by bees. Similar to allergic patients after BV-SIT, these naturally anergized individuals showed a substantial increase in IL-10-producing CD4 ϩ CD25 ϩ T cells and monocytes. Neutralization of endogenous IL-10 in cell cultures of naturally anergized individuals fully reconstituted the proliferative T cell and cytokine responses (15) .
IL-10 is a major regulatory cytokine of inflammatory responses. It was originally described as a Th2 cell factor in the mouse, inhibiting cytokine synthesis by Th1 cells (31) . However, increasing evidence showed that IL-10 acts as a general inhibitor of proliferative and cytokine responses of both Th1 and Th2 cells in vitro and in vivo (32) (33) (34) (35) (36) (37) (38) . IL-10 is released by mononuclear phagocytes (32, 33) , natural killer cells (34) , and both Th1 and Th2 lymphocytes (35) . The inhibitory effect of IL-10 in T cell clones was observed exclusively in APC-dependent culture systems, but not in T cells stimulated by solid-phase bound anti-CD3 (33, 36, 37, 39) . The reason for this may be that IL-10 blocks the CD28-B7.1 interaction and subsequent costimulatory signaling pathways in T cells (38) . Thus, inhibition of accessory molecule signaling may explain peptideligand-induced specific anergy in certain T cell systems (30, 40) . In addition, IL-10 action at the level of cytokine gene transcription (41) and inhibition of cytokine mRNA accumulation has been demonstrated (42) .
In mice, IL-10 administration before allergen treatment induced antigen-specific T cell tolerance and demonstrated the pivotal role of IL-10 in establishment of peripheral T cell anergy. (43) . Moreover, inhibition of graft-vs.-host disease by IL-10 and allograft rejection in HLA mismatched, bone marrow transplanted SCID patients provide further evidence for a key role of this cytokine in the induction and maintenance of an anergic state (44) . Similarly, inappropriate stimulation of tumor reactive human T cells was shown to result from increased endogenous IL-10 production by these cells (45) , indicating a role for IL-10 in tumor-specific anergy. Recently, IL-10-derived regulatory CD4
ϩ T cells producing IL-10, but not IL-2 and IL-4, that suppressed antigenspecific T cell response in vitro and prevented antigen-induced murine colitis were identified in humans and mice (46) .
Additional evidence for IL-10-induced anergy in specific immunotherapy
Induction of peripheral T cell anergy resulting from IL-10 released by specific immunotherapy was clearly demonstrated in allergy to honey bee and wasp venom (11, (13) (14) (15) . Furthermore, induction of T cell nonresponsiveness was observed in specific T cell peptide treatment of cat allergy (17) , similar to the PLA-peptide immunotherapy of bee venom allergy (16) . Moreover, down-regulated T cell proliferative responses were found in specific immunotherapy of atopic patients with allergic rhinitis, conjunctivitis, and asthma (25, 26) . Evidence for increased IL-10 in nasal allergy and asthma immunotherapy has been shown in two recent studies. In successful ragweed nasal immunotherapy, the group receiving nasal weed extract had elevated IL-10 levels in nasal lavage at the peak of ragweed season compared with those treated with placebo (47) . In addition, increased plasma IL-10 levels have been found in grass pollen immunotherapy of asthma after 24 h of initiation (48) . Together, these studies demonstrate the pivotal role of IL-10 in suppressing the T cell responses in specific immunotherapy and implicate the generation of an anergic state in T lymphocytes as a general regulatory mechanism of specific immune responses.
Specific responses can be reestablished in anergic T cells by cytokines from the tissue microenvironment
The abrogated proliferative response after SIT was almost fully recovered by stimulation of anergic cells in the presence of antigen and IL-2 or IL-15 (14) . The full capacity for IFN-␥ secretion was reestablished by both cytokine treatments (Fig. 3) . In contrast, specific stimulation in the presence of IL-4 induced IL-4, IL-5, and IL-13, and therefore recovered a Th2 cytokine pattern typical for an allergic ϩ T cells). After fixing and permeabilizing, the cells were counterstained for intracytoplasmic IL-10. PLA-specific T cells were derived from PLAstimulated PBMC that were cultured for 10 days and T cells were restimulated with an anti-CD3/anti-CD28 mixture in the presence of monensin for 5 h The yellow area represents the isotype control Ab, blue curve before SIT, and red curve 7 days after SIT.
state (14) . IL-2 is produced mainly by activated T cells. However, basically the same immunological properties are displayed by IL-15 secreted by most antigen-presenting cell types and tissue cells, but not by T cells (49) . Thus, IL-15, but also IL-2, may act as important microenvironmental cytokines that regulate and recover T cells from SIT-induced anergy. Certain cytokines from the tissue microenvironment can control the secondary induction of distinct Th1 or Th2 cytokine patterns associated with either normal immunity and successful therapy or further persistence of allergy. In particular, IL-15, being released by professional antigen-presenting cells and various tissue cells in normal immune defense, may direct anergic T cells toward normal immunity. In contrast, long-lasting success of SIT to single allergen may be difficult to achieve in an already established polyallergic and atopic individual.
Regulation of specific IgE and IgG4 antibodies in SIT and PIT
The serum levels of specific IgE and IgG4 antibodies delineate allergic and normal immunity to allergen (6, 20, 24, 50, 51) . Whereas peripheral anergy was demonstrated in specific T cells, the capacity by B cells to produce specific IgE and IgG4 antibodies was not abolished. Specific serum levels of both isotypes increased during the early phase of treatment, but the increase in specific IgG4 was more pronounced and the ratio of specific IgE to IgG4 was decreased by 10-to 100-fold (14, 16, 24, 52) . Also, the in vitro production of PLA-specific IgE and IgG4 antibodies by PBMC changed in parallel with the serum levels of specific isotypes (14) . Similar changes in specific isotype ratio have been observed in SIT of various allergies (53) (54) (55) . IL-10 induced and increasingly secreted by SIT appears to counter-regulate antigenspecific IgE and IgG4 antibody synthesis. It is a potent suppresser of both total and PLA-specific IgE, while IgG4 formation is simultaneously increased (15, 56) . Thus, in SIT, IL-10 not only generates anergy in T cells, but also counter-regulates specific isotype formation and changes the response from an IgE-to an IgG4-dominated phenotype.
The effect of IL-10 on the effector cells of allergic inflammation
At a very early stage of BV-SIT, most patients are already protected against bee stings even though a definite decrease in IgE antibodies and IgE-mediated skin sensitivity normally requires several years of treatment (1, 57) . Increase of allergen-specific IgG4 antibodies blocking IgE binding could explain only the late phase protection of SIT (48, 57) . At the early phase, however, a decrease in the histamine and sulfidoleukotrienes release from basophils may be more relevant (58) . This decreased basophil mediator releasability can be attributed to suppression of cytokines in anergic T cells. There is clear evidence that effector cells of the allergic inflammation (mast cells, basophils, and eosinophils) require T cell cytokines for priming, survival, and activity (59 -63) . Moreover, IL-10 was shown to reduce generation of tumor necrosis factor ␣, granulocyte-macrophage colony-stimulating factor, and IL-6 from mouse bone marrow and rat peritoneal mast cells in response to specific IgE cross-linking (64, 65) . In addition, IL-10 down-regulates eosinophil function and activity (66) . IL-10 suppresses IL-5 production by human resting T cells and in Th0 and Th2 clones (37, 38) . The inhibitory action of IL-10 on IL-5 synthesis and eosinophil recruitment has been confirmed in a murine model of allergic eosinophilic peritonitis and airway eosinophilia (36, 37) . Furthermore, IL-10 inhibits endogenous granulocyte-macrophage colony-stimulating factor production and CD40 expression by activated eosinophils and enhances eosinophil death (67, 68) .
CONCLUDING REMARKS
Induction of specific anergy in peripheral T cells by autocrine IL-10 production and subsequent reactivation of distinct cytokine patterns by different cytokines from the microenvironment are pivotal key steps in the immunological mechanism of specific allergy treatment (Fig. 4) . This mechanism, however, has implications that may reach beyond allergy treat- ment and IgE antibody regulation. Induction and maintenance of specific anergy may be important steps in transplantation and treatment of autoimmunity. Furthermore, it may lead to a better understanding of tumor growth, parasite infection, and development of AIDS (18, 44, 45, 69, 70) . Both SIT and PIT generate high amounts of IL-10, which, in turn, induces specific anergy in peripheral T cells, apparently without directly inhibiting B cell function. As a result of these treatments, the antigenspecific IgE:IgG4 ratio in peripheral blood decreases toward normal. Moreover, specific Th2 cytokine reactivity is directly involved in the pathogenesis of allergic inflammation, since these cytokines are essential for priming, survival, and activity of inflammatory effector cells. IL-10, initially produced by the specific T cells themselves not only induces anergy, but also inhibits the inflammatory reaction by inactivating mast cells, basophils, and eosinophils.
Many studies affirm that SIT is not always successful (55, 71) . The reactivation of anergic T cells and the modulation of cytokine patterns suggest a decisive role of microenvironmental cytokines in directing SIT toward success or failure. High success rates of more than 90% are observed mainly in mono-or oligo-specific allergies, occurring mostly in venomallergic individuals (55, 71) . They display a normal immune microenvironment, reactivating a Th0-Th1 cytokine pattern and normal IgG4 antibody response. In contrast, highly polyallergic or atopic states are characterized by increased IL-4 contents, which may reestablish a Th2 allergic response. Moreover, increased IL-10 contents in T cells during SIT may represent a predictive measure, avoiding longterm treatment over several years in unsuccessful cases.
Finally, the biochemical pathways of anergy induction and maintenance remain to be determined. The inhibitory effect of IL-10 in T cells was observed exclusively in APC-dependent culture systems and antigen-specific responses, and not in T cells stimulated by solid-phase bound anti-CD3. The objective for this is that IL-10 blocks the CD28 stimulation and subsequent costimulatory signaling pathways in T cells (72) . Lack of signaling through CD28, even in the presence of an optimal TcR signal, can render the cell anergic (73) . Although CD28 can display its signaling potential through an array of intermediates, the phosphatidylinositol 3 (PI 3) kinase has the greatest affinity for CD28. The PI 3 kinase appears to deliver, in synergy with TcR signals, an activation signal for the AP-1 component, c-jun. The activation of PI 3-kinase depends on membrane localization through binding by its SH2 domain to a conserved motif in the cytoplasmic domain of CD28 (74) . Indeed, in results not yet published, we found that IL-10 is active on T cells that require CD28 costimulation for proliferation and cytokine production. IL-10 ligation to its receptor blocks the tyrosine phosphorylation of CD28. This leads to an inhibition of CD28 association to p85 PI 3-kinase and inhibition of CD28 signaling pathway. These results also support the relevance of the experimental model of anergy induction in human T cells lacking a costimulatory signal (19, 30, 40) . Accordingly, SIT and PIT are clearly based on immunological and biochemical mechanisms, also explaining the resulting clinical effect of the treatment. This knowledge may help to improve SIT, and further defining biochemical signaling pathways may open new strategies of immune suppression by drug interaction. 
